ADMA Biologics Has Received FDA Approval For Its Tenth ADMA BioCenters Plasma Collection Facility In Laurel, Maryland. This Plasma Collection Facility Commenced Operations And Initiated Source Plasma Collection In 1H Of 2023
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics has received FDA approval for its tenth plasma collection facility, ADMA BioCenters, located in Laurel, Maryland. The facility began operations and started collecting source plasma in the first half of 2023.
November 16, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics' new FDA-approved plasma collection facility in Maryland is operational, potentially increasing the company's plasma collection capacity and contributing to its growth.
The approval and commencement of operations of ADMA Biologics' new plasma collection facility is likely to have a positive short-term impact on the company's stock price. Increased capacity for plasma collection can lead to higher production volumes for their plasma-based therapies, which in turn could result in increased revenues. Investors may view this expansion as a sign of growth and a step towards achieving greater economies of scale.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100